Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing
about
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics TestingMerging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.Implementation and utilization of genetic testing in personalized medicine.Pharmacogenetics in clinical practice: how far have we come and where are we going?Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosingPharmGKB summary: very important pharmacogene information for human leukocyte antigen B.EHR based Genetic Testing Knowledge Base (iGTKB) Development.Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.Preemptive clinical pharmacogenetics implementation: current programs in five US medical centersClinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.HLA-B (*) 58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand.Pharmacometabolomics Informs Viromics toward Precision Medicine.Crystal arthritis: Is HLAB genotyping the future of gout pharmacogenomics?Development and use of active clinical decision support for preemptive pharmacogenomics.Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testingImpact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Integrating pharmacogenetic information and clinical decision support into the electronic health record.Personalized medicine in cardiology: the time for genotype-guided therapy is now.HLA and disease: guilt by association.Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective.PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.Genomic architecture of pharmacological efficacy and adverse events.Role of dermatology in pharmacogenomics: drug-induced skin injury.Pharmacogenetic considerations in the treatment of gout.Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.Clinical application of pharmacogenetics: focusing on practical issues.Allopurinol hypersensitivity: investigating the cause and minimizing the risk.Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update.Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis.Evidence and resources to implement pharmacogenetic knowledge for precision medicine.Recent advances in understanding and managing goutLong read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes.Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
P2860
Q24567778-3BA3A659-E4F3-453C-B664-369E5E3E29C2Q26800980-20259540-0CD1-4F84-938B-0ECD013A4E85Q28079766-D4940214-B3CD-49D7-879B-A85458527CC4Q31058146-D7CB62FF-DAA0-461B-97A7-D147D5533CE0Q33666857-71BF4E33-F683-4608-80D4-D47EE12C9302Q33953373-6DA30989-5640-4AE4-BEC0-32E04A618A91Q34147916-77A5C57C-24FE-4F4A-AD8B-BF2F1C9DCCA3Q34343365-21281FF8-C54A-468E-A777-4211AC28F805Q34345953-3AE596BE-8782-4F69-8B16-179C087DBA7DQ34389432-10AFF857-6679-4C27-A94F-725DD0EF01CFQ35168561-1A685F80-E184-4084-9AF5-60DC86BC9903Q35852441-59D1796D-B24A-433C-BFDD-D532CFFA5972Q36085404-7E6B66D2-FC53-44AE-800F-C93A65A9043EQ36166107-D839906D-01AC-44B8-9647-CFC584243210Q36362974-2693EEC3-A7D9-4801-BC6D-84924303CFF5Q36398661-D64783D6-3845-4AF2-87E9-A26911252D75Q37100410-AD0576AC-8E62-49A9-860D-52B153946C4DQ37368628-8BF81BC6-2602-4819-90A6-2AD99E3CC441Q37507172-0A819995-1E36-4D85-A403-5967B116715CQ37642949-19F816D6-3BCC-49E3-B395-0D36A2F90AA6Q37652863-17AF4974-7F38-4E1C-9608-CBABF5D411AAQ37697237-E1243481-9FAC-489F-869F-8979CD91928AQ37715400-D8718839-3A0B-42DB-AEE5-389BBB6F51B5Q38120086-33233759-5319-4578-9520-208801DA523BQ38134171-64AE7BCB-C54B-4C59-B451-A80318B0B12CQ38164730-753A8474-9AE9-45D5-AE71-601155D4DF49Q38219092-EC23C90E-A733-4708-AC39-0AA648F77676Q38292930-091D2B07-1790-4800-8AC4-928DF74B9850Q38396234-89A82AE8-CCEF-45B6-9EA0-F15DDFBDB0B6Q38422218-AD021539-10A6-49D9-A66A-5466AC10AE8AQ38474868-47AA225A-3505-4C59-8AA0-3B22651CA8BFQ38593942-740C7391-F533-472B-ACE5-5A4C4D703845Q38594891-710861D1-9F3D-4113-B6F0-FBF7325EEB1CQ38611191-1854E411-2CD7-46E3-A22A-0DC5DFF043CEQ38629821-21C70B6B-9DBD-4D16-9E15-6F44BD4A849BQ38654435-448E190E-788D-4997-8912-4990B1563CB4Q39173298-DECCF508-949E-4741-8E9B-4CEACDF0BA41Q39207801-3BD8C0F9-87D7-428C-8D41-BAEE4444BE9BQ39496541-52874C61-C1F9-42AB-AD0A-AF7BDC515EB5Q40915728-0676F9AE-629E-4369-B638-10B94F769E71
P2860
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing
@ast
Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing
@en
Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing
@nl
type
label
Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing
@ast
Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing
@en
Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing
@nl
prefLabel
Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing
@ast
Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing
@en
Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing
@nl
P2093
P2860
P3181
P356
P1476
Clinical Pharmacogenetics Impl ...... enotype and allopurinol dosing
@en
P2093
J T Callaghan
M S Hershfield
T Mushiroda
W Tassaneeyakul
P2860
P3181
P356
10.1038/CLPT.2012.209
P407
P577
2013-02-01T00:00:00Z